- PLN138.21m
- PLN134.59m
- PLN6.02m
Brief: Molecure FY Net Loss Widens To 18.3 Mln Zlotys
Brief: Molecure Gets About 32.5 Mln Zloty Subsidy From PARP
Brief: Black Forest SICAV-SIF Lowers Stake In Molecure To 4.95%
Brief: Molecure Gets Proof Of Concept For mRNA Platform
Brief: MS Galleon Directly Holds 20% Stake In Molecure
Brief: Molecure Q3 Net Loss Widens To 4.2 Mln Zlotys
Brief: Molecure Says PARP Positively Evaluates Subsidy For Its Project
Brief: Molecure H1 Net Loss Widens To 7.4 Mln Zlotys
Brief: Molecure Says US IRB Okays Second Phase Of Study For OATD-01
Brief: U.S. FDA Gives Green Light To Molecure's Flagship Program
Brief: Molecure To Begin Phase II Clinical Trial Of OATD-01 In US
Brief: Molecure Completes About 50 Mln Zlotys SPO
Brief: Molecure Sums Up H Series Shares Subscription
Brief: Molecure Signs Deal For Phase II Clinical Trial Of OATD-01
Brief: Molecure Files IND To US FDA For OATD-01
Brief: Molecure Q1 Net Loss Narrows To 3.2 Mln Zlotys
Brief: Molecure To Get About 6.9 Mln Zlotys Of 2020 Tax Overpayment
Brief: Molecure Announces First Patient Dosed In Phase I Trial With Novel, First-In-Class Dual Arginase Inhibitor OATD-02
Brief: Molecure To Regain Worldwide Rights To Dual Chitinase Inhibitor Oatd-01